Sellas Life Sciences is trading 4.11% down at $10.85 on October 8, 2026; no new company announcement directly explains the decline. - Coverage notes a fresh AML study circulating as investors await the REGAL trial’s final-analysis milestone; causation is unconfirmed. - Higher oil prices and Treasury yields are pressuring equities, but major-index moves do not confidently explain this stock-specific decline. No reliable current volume figure was found.